THOMSON REUTERS INTEGRITY SM

Transcription

1 THOMSON REUTERS INTEGRITY SM DISCOVER THE UNDISCOVERED Jenna OH Solution Consultnat, Life Science

2 OBJECTIVES By the end of this module you will be able to: State key strengths of Thomson Reuters Integrity which differentiate it from other pipeline databases Identify the contents provided in Integrity Understand the unique features of Integrity Address benefits you can get from Integrity 2

3 AGENDA Introduction of Integrity Contents of Integrity Benefit of yours by using Integrity Live Demo 3

4 LS solutions for the Pharmaceutical Industry Cortellis for Competitive Intelligence BD/Licensing Cortellis for Clinical Trials Intelligence 4

5 Life Sciences Decision Support from Thomson Reuters Disease Biology Drug R&D Drug Pipeline Regulatory Thomson Reuters MetaCore Biological pathway and target discovery Thomson Reuters Integrity Cross-disciplinary content Thomson Reuters Pharma & Newport Integrated business and science content IDRAC Regulatory decision support Manually curated biological pathway maps Chemistry, genomics, biomarkers & pathology data Target discovery and drug repositioning Drugs pipeline and patent content for early stage research Biology, chemistry and pharmacology data Biomarkers module linking drugs, targets and genes to biomarkers Drug pipeline, deals, sales forecasts, select patent & scientific information Generic drug Intelligence Current awareness and competitive intelligence Market information, patent expiry, API manufacturers Regulatory environment in 70 global markets Value add explanatory documents and regulatory Intelligence Understand disease and enrich your pathway insight Identify upstream and downstream effects Integrate proprietary data with public knowledge Understand disease, select drug targets Demonstrate safety and efficacy Design experiments Evaluate market opportunities and competitors pipelines Source / evaluate licensing and acquisition deals identify / evaluate generic drug opportunities Design global regulatory submission / drug approval strategies

6 What is Integrity?

7 JOINING THE DOTS: UNDERSTANDING THE MOLECULAR BASIS OF DISEASE USING MANUAL CURATION 9045 Publications with BRCA1 & Cancer in title/abstract* BRCA Publications with BRCA1 in title/abstract* ~1 hour per paper = 377 days without sleep/rest! ~1 hour per paper = 412 days without sleep/rest! *Searches performed 8 th of Aug 2013 in Pubmed

8 THOMSON REUTERS INTEGRITY INTEGRATED SCIENTIFIC INTELLIGENCE Thomson Reuters Integrity is a scientifically-focused drug R&D database that accelerates early stage drug research. Integrity enables organizations to make better informed decisions earlier in the research process regarding: which projects to start or stop; which drug targets to work on; and which lead compounds to prioritize. 8

9 INTEGRITY AND CORTELLIS FOR CI Integrity More Scientific details Info to help identify and validate biological targets and lead compounds Stronger in Preclinical stages/disease & target demonstration Cortellis for CI More Commercial details Info to help identify and validate companies as M&A or partnership candidates Stronger in Clinical stages and post launch 9

10 INTEGRITY AND METACORE Metacore Provides molecular understanding of disease Analyze and undersand experimental findings (Omics data) in the context of validated biological pathway Generate hypotheses around novel targets, biomarkers, mechanisms of action Integrity Provides pharmaceutical pipeline competitor intelligence for the scientific researchers Prioritize research activities with evaluation of prior art and competitors Validate hypotheses with biomarker, drug, chemistry, pharmacology and PK content 10

11 What benefits come to you?

12 CRITICAL BUSINESS ISSUES AT THIS EARLY STAGE? What should we work on next? Have we missed something? Is our compound novel? Do we have all the facts to back up our decision? Do we have freedom to operate? Is our compound better than the competition? 12

13 INTEGRITY S KEY STRENGTHS Integrated biological, chemical and pharmacological data to provide insights and support decision-making. A focus on Scientific Intelligence, including detailed pharmacokinetic (PK) and pharmacology data points for benchmarking experimental performance of compounds. Extensive coverage of Early Stage Research to ensure you don t miss any important competitive compounds Biology Pharmacology Chemistry 13

14 Benefits from using Integrity Enhance your productivity With Integrity you can find in minutes what might take several days with other resources. This frees up time for core research activities, planning and analysis Make more informed decisions with greater confidence The information in Integrity is carefully refined from multiple sources and cross-correlated by our experts. As a result you can get an overview of the current drug or target landscape, and stay on top of important developments with minimal effect. Benchmark the performance of your compounds To guide prioritization decisions- quickly identify in vitro, in vivo and human points, and details of the assays used to see how you compare to the competition. 14

15 What contents are provided?

16 Managing Information Budgets Multiple Data Sources Patent offices WO (PCTs), EP, JP, US, CN, IN, KR Biomedical literature >15,000 journals Congresses, symposia, meetings > 400/year Company information > 6063 organizations Regulatory information Scientific websites Clinical Trial Registries Press Releases Access to 13 Knowledge Areas Drugs & Biologics Targets Genomics Organic Synthesis Experimental Pharmacology Experimental Models Biomarkers* Pharmacokinetics / Metabolism Clinical Studies Disease Briefings Companies & Research Institutions Literature Patents Maximizing Resources A team of over 80 indexers manually index data, saving your organization the cost of staffing, managing this effort and the risk of missing something crucial with an adhoc effort. 16

17 INTEGRATED SCIENTIFIC INTELLIGENCE Biology Targets; Genomics; Biomarkers. Clinical Studies Disease Briefings Drugs and Biologics Pharmacology; Animal Models; Pharmacokinetics. Pharmacology Chemistry Structures; Organic Synthesis 17

18 Integrity Contents Growth 2013 Knowledge Area Counts as of July Drugs & Biologics 404,572 Targets & Pathways 2,268 Genomics 24,825 Biomarkers 22,006 Organic Synthesis & Intermediates 25,159 Experimental Pharmacology 1,344,915 Experimental Models 11,448 Pharmacokinetics/metabolism 559,497 Clinical Studies 202,190 Disease Briefings 141 Company & Research Institutions 10,156 Literature 1,615,398 Patents 226,655 18

19 EXAMPLE: Searching paclitaxel in Integrity You can find the detail info of paclitaxel in terms of related biomrker, experimental pharmacology, experimental model, disease briefing, etc. as the below. 19

20 EXAMPLE: Drugs & Biologics 20

21 EXAMPLE: Statistic analysis 21

22 Experimental Pharmacology 22

23 EXAMPLE: Target& Pathway Search 23

24 EXAMPLE: Target& Pathway Search 24

25 EXAMPLE: Experimental model You can see which experimental model has been used for the condition of interest. You can check what is the best model for the condition of your interest. able to be filtered by

26 EXAMPLE: Synthetic routes You can see how it is able to be synthesized. You can check what approach has been explored. 26

27 Biomarker Modules: Add-on

28 Paradigm Change In-depth of understanding on pathogenesis/mechanism of disease One size fits all Strategy Ex: Paclitaxel Biomarkers reliably predict the patients of target: Companion Diagnosis Development of Technology Ex: Biomarker Personalized medicine Ex: Pertuzumab 28

29 INTEGRITY BIOMARKER ROLES Disease/Toxicity Profiling Risk Factor Screening Diagnosis (Differential diagnosis) Staging Prognosis Monitoring Disease Progress Detection of Recurrence Predicting Treatment Efficacy / Toxicity Monitoring Treatment Efficacy / Toxicity Prediction of Drug Resistance Selection for Therapy 29

30 Biomarkers Module A manually indexed database of biomarker information from diverse sources, fully integrity in Integrity The only database that supports biomarker research across the entire profile of a disease: Proof-of mechanism; safety/treatment monitoring; risk detection and outcomes measurement 30

31 Biomarker Module Allows you to see at-a-glance how well-established a specific biomarker use is: Make more informed decisions around your marker research with greater confidence Validity Emerging Experimental Early studies in humans Late studies in human Recommended/approved 31

32 Biomarker module Biomarker Record Biomarker Uses Related information 32

33 Thanks you! Jenna OH Any Question? Solution Consultant Life Sciences, Thomson Reuters Cheng-Chih Eric Huang Sales Manager, Taiwan Life Sciences, Thomson Reuters eric.huangcc@thomsonreuters.com 33